J Korean Diabetes.  2024 Sep;25(3):145-149. 10.4093/jkd.2024.25.3.145.

Management Strategies for Children and Adolescents with Diabetes Mellitus

• Cho JH

• KMID: 2559570
• DOI: http://doi.org/10.4093/jkd.2024.25.3.145

Abstract

The principles of treatment for diabetes in children and adolescents cannot simply be derived from care routinely provided to adults with diabetes. The major consideration is that the epidemiology, pathophysiology, developmental considerations, and response to treatment of pediatric diabetes are often different from those of adult diabetes. Second, recommended treatments for children and adolescents with type 1 diabetes (T1DM), type 2 diabetes (T2DM), and other pediatric conditions such as monogenic diabetes (neonatal diabetes and MODY [maturity-onset diabetes of the young]) also differ. HbA1c goals in T1DM and T2DM must be individualized and reassessed over time. A HbA1c < 7% is appropriate for many children and adolescents with T1DM. In a case with hypoglycemia, hypoglycemic unawareness, lack of access to analog insulins, advanced insulin delivery technology and/or continuous glucose monitoring, a less stringent HbA1c < 7.5% will be required. A reasonable HbA1c goal for T2DM is < 7%. If possible, a strict HbA1c target of < 6.5% can be implemented. Metformin is the first-line treatment of choice in T2DM. In a case with ketosis or HbA1c > 8.5%, insulin will be required with once daily basal insulin (0.25~0.5 IU/kg). If the glycemic goal is not attained, the addition of a second agent is considered in adult patients but might not be applicable or safe in pediatric cases. Therefore, the efficacy and safety of these drugs used in adult patients, including glucagon-like peptide-1 receptor agonists and sodium glucose cotransporter 2 inhibitors, should be evaluated in pediatric patients worldwide.

Keyword

Adolescent; Child; Diabetes mellitus; Diabetes mellitus, type 1; Diabetes mellitus, type 2

Reference

1.American Diabetes Association Professional Practice Committee. 14. Children and adolescents: standards of care in diabetes-2024. Diabetes Care. 2024. 47(Suppl 1):S258–81.

2.Korean Diabetes Association. 2023 Clinical practice guide-lines for diabetes. 8th ed.Seoul: Korean Diabetes Association;2023. p. 124–77.

3.Korean Diabetes Association Education Committee. The guide for diabetes education. 4th ed.Seoul: Korean Diabetes Association;2019. p. 243–7.

4.Debuysschere C., Nekoua MP., Alidjinou EK., Hober D. The relationship between SARS-CoV-2 infection and type 1 diabetes mellitus. Nat Rev Endocrinol. 2024. doi: 10. 1038/s41574-024-01004-9. [Epub ahead of print].

5.Gomber A., Ward ZJ., Ross C., Owais M., Mita C., Yeh JM, et al. Variation in the incidence of type 1 diabetes mellitus in children and adolescents by world region and country in-come group: a scoping review. PLOS Glob Public Health. 2022. 2:e0001099.

6.Chae HW., Seo GH., Song K., Choi HS., Suh J., Kwon A, et al. Incidence and prevalence of type 1 diabetes mellitus among Korean children and adolescents between 2007 and 2017: an epidemiologic study based on a national database. Diabetes Metab J. 2020. 44:866–74.

7.Lee J., Kim JH. Diabetes in adolescence, appropriate tran-sition to adult clinic. J Korean Diabetes. 2021. 22:77–84.

8.Korean Diabetes Association. Diabetes fact sheet in Korea 2015. Seoul: Korean Diabetes Association;2015.

9.Bergenstal RM., Tamborlane WV., Ahmann A., Buse JB., Dailey G., Davis SN., STAR 3 Study Group, et al. Effective-ness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med. 2010. 363:311–20.

10.Rytter K., Schmidt S., Rasmussen LN., Pedersen-Bjergaard U., Nørgaard K. Education programmes for persons with type 1 diabetes using an insulin pump: a systematic review. Diabetes Metab Res Rev. 2021. 37:e3412.

11.Laranjeira FO., de Andrade KRC., Figueiredo ACMG., Silva EN., Pereira MG. Long-acting insulin analogues for type 1 diabetes: an overview of systematic reviews and meta-analysis of randomized controlled trials. PLoS One. 2018. 13:e0194801.

12.Little SA., Speight J., Leelarathna L., Walkinshaw E., Tan HK., Bowes A, et al. Sustained reduction in severe hypoglycemia in adults with type 1 diabetes complicated by impaired awareness of hypoglycemia: two-year follow-up in the HypoCOMPaSS randomized clinical trial. Diabetes Care. 2018. 41:1600–7.

13.Shah AS., Zeitler PS., Wong J., Pena AS., Wicklow B., Arslanian S, et al. ISPAD Clinical Practice Consensus Guide-lines 2022: type 2 diabetes in children and adolescents. Pediatr Diabetes. 2022. 23:872–902.

14.Karavanaki K., Paschou SA., Tentolouris N., Karachaliou F., Soldatou A. Type 2 diabetes in children and adolescents: distinct characteristics and evidence-based management. Endocrine. 2022. 78:280–95.

15.Gandica R., Weinstock RS., Gunaratne M., Arslanian S., Doherty L., Geffner ME., TODAY Study Group, et al. Long-term retention of young adult study participants with youth-onset type 2 diabetes: results from the TO-DAY2 study. Horm Res Paediatr. 2023. 96:325–31.

16.Chadda KR., Cheng TS., Ong KK. GLP-1 agonists for obe-sity and type 2 diabetes in children: systematic review and meta-analysis. Obes Rev. 2021. 22:e13177.

17.Bjornstad P., Drews KL., Caprio S., Gubitosi-Klug R., Nathan DM., Tesfaldet B., TODAY Study Group, et al. Long-term complications in youth-onset type 2 diabetes. N Engl J Med. 2021. 385:416–26.